Opiranserin Explained

Opiranserin (; developmental code name VVZ-149) is a selective and combined glycine GlyT2 transporter blocker (= 0.86 μM), purine P2X3 receptor antagonist (= 0.87 μM), and serotonin 5-HT2A receptor antagonist (= 1.3 μM) which is under development by Vivozon for the intravenous treatment of postoperative pain.[1] [2] [3] [4] As of April 2017, it is in phase II clinical trials for this indication. The of the drug was issued in 2017.[2]

Notes and References

  1. Pang MH, Kim Y, Jung KW, Cho S, Lee DH . A series of case studies: practical methodology for identifying antinociceptive multi-target drugs . Drug Discov. Today . 17 . 9–10 . 425–34 . 2012 . 22269134 . 10.1016/j.drudis.2012.01.003 .
  2. http://apps.who.int/medicinedocs/documents/s23256en/s23256en.pdf
  3. Web site: Opiranserin - Vivozon - AdisInsight. adisinsight.springer.com.
  4. Nedeljkovic SS, Correll DJ, Bao X, Zamor N, Zeballos JL, Zhang Y, Young MJ, Ledley J, Sorace J, Eng K, Hamsher CP, Maniam R, Chin JW, Tsui B, Cho S, Lee DH . Randomised, double-blind, parallel group, placebo-controlled study to evaluate the analgesic efficacy and safety of VVZ-149 injections for postoperative pain following laparoscopic colorectal surgery . BMJ Open . 7 . 2 . e011035 . 2017 . 28213593 . 5318554 . 10.1136/bmjopen-2016-011035 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Opiranserin".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.